ORUKA THERAPEUTICS INC (ORKA) Stock Price, Quote, News and Overview
NASDAQ:ORKA - Nasdaq - US6876041087 - Common Stock - Currency: USD
ORKA Quote, Performance and Key Statistics
12.56
-0.31 (-2.41%)
The current stock price of ORKA is 12.56 USD. In the past month the price increased by 32.77%.
ORKA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.61 | 337.52B | ||
| AMGN | AMGEN INC | 14.22 | 158.74B | ||
| GILD | GILEAD SCIENCES INC | 14.21 | 136.81B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 116.96B | ||
| REGN | REGENERON PHARMACEUTICALS | 11.94 | 57.14B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 40.16B | ||
| ARGX | ARGENX SE - ADR | 100.5 | 35.29B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.9 | 29.17B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.62B | ||
| NTRA | NATERA INC | N/A | 22.58B | ||
| BIIB | BIOGEN INC | 8.26 | 19.14B | ||
| INSM | INSMED INC | N/A | 17.98B |
Related stock screener links
About ORKA
Company Profile
Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. The company is headquartered in Menlo Park, California and currently employs 28 full-time employees. The company went IPO on 2000-07-21. The firm is focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. ORKA-001 is an extended half-life monoclonal antibody (mAb) designed to target IL-23p19. IL-23 is a pro-inflammatory cytokine that plays a critical role in the proliferation and development of T helper 17 (Th17) cells, which are the primary drivers of several autoimmune and inflammatory disorders, including PsO. IL-23 is composed of two subunits: a p40 subunit and a p19 subunit. ORKA-002 is an extended half-life mAb designed to target IL-17A and IL-17F (IL-17A/F).
Company Info
ORUKA THERAPEUTICS INC
855 Oak Grove Ave., Suite 100
Menlo Park CALIFORNIA US
Employees: 28
Phone: 16506067910
ORUKA THERAPEUTICS INC / ORKA FAQ
What is the stock price of ORUKA THERAPEUTICS INC today?
The current stock price of ORKA is 12.56 USD. The price decreased by -2.41% in the last trading session.
What is the ticker symbol for ORUKA THERAPEUTICS INC stock?
The exchange symbol of ORUKA THERAPEUTICS INC is ORKA and it is listed on the Nasdaq exchange.
On which exchange is ORKA stock listed?
ORKA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ORUKA THERAPEUTICS INC stock?
15 analysts have analysed ORKA and the average price target is 40.93 USD. This implies a price increase of 225.86% is expected in the next year compared to the current price of 12.56. Check the ORUKA THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ORUKA THERAPEUTICS INC worth?
ORUKA THERAPEUTICS INC (ORKA) has a market capitalization of 470.25M USD. This makes ORKA a Small Cap stock.
How many employees does ORUKA THERAPEUTICS INC have?
ORUKA THERAPEUTICS INC (ORKA) currently has 28 employees.
What are the support and resistance levels for ORUKA THERAPEUTICS INC (ORKA) stock?
ORUKA THERAPEUTICS INC (ORKA) has a support level at 12.55 and a resistance level at 12.59. Check the full technical report for a detailed analysis of ORKA support and resistance levels.
Should I buy ORUKA THERAPEUTICS INC (ORKA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ORKA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ORKA, evaluating the profitability, health, valuation and growth aspects
- ORUKA THERAPEUTICS INC (ORKA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ORUKA THERAPEUTICS INC (ORKA) Sales and EPS estimates to see what analysts future expectations are.
- ORUKA THERAPEUTICS INC (ORKA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ORUKA THERAPEUTICS INC (ORKA) Insider and Institutional Ownership to learn about the owners and their transactions.
- ORUKA THERAPEUTICS INC (ORKA) Stock Chart to make your own analysis
- ORUKA THERAPEUTICS INC (ORKA) Latest news and press-releases to stay up to date.
Does ORUKA THERAPEUTICS INC (ORKA) stock pay dividends?
ORUKA THERAPEUTICS INC (ORKA) has a dividend yield of 12.84%. The yearly dividend amount is currently 0. Check the full fundamental report for a detailed analysis of ORKA dividend history, reliability and sustainability.
When does ORUKA THERAPEUTICS INC (ORKA) report earnings?
ORUKA THERAPEUTICS INC (ORKA) will report earnings on 2025-07-30.
What is the Price/Earnings (PE) ratio of ORUKA THERAPEUTICS INC (ORKA)?
ORUKA THERAPEUTICS INC (ORKA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-5.57).
What is the Short Interest ratio of ORUKA THERAPEUTICS INC (ORKA) stock?
The outstanding short interest for ORUKA THERAPEUTICS INC (ORKA) is 7.63% of its float. Check the ownership tab for more information on the ORKA short interest.
ORKA Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to ORKA.
ORKA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ORKA. While ORKA has a great health rating, there are worries on its profitability.
ORKA Financial Highlights
Over the last trailing twelve months ORKA reported a non-GAAP Earnings per Share(EPS) of -5.57. The EPS decreased by -101.2% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -27.77% | ||
| ROE | -28.71% | ||
| Debt/Equity | 0 |
ORKA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 89% to ORKA. The Buy consensus is the average rating of analysts ratings from 15 analysts.